A 2025 early clinical study involving 15 volunteers found that a single infusion of an experimental CRISPR-based gene-editing drug reduced cholesterol levels and harmful triglyceride levels by about 50%.
November 08, 2025
high
temporal
Early-phase clinical study reporting lipid-lowering effects of a CRISPR-based therapeutic.